By Fineline Cube 
China-based Jiangxi Jemincare Group has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Italy-based Chiesi Farmaceutici SpA’s Clenil (beclomethasone), marking the first generic version of the drug to be approved in China. The approval positions Jemincare as a key player in the domestic asthma treatment market.
Regulatory Approval and Market Context
Clenil, originally approved in China in 2013, is indicated for the treatment of asthma and the improvement of bronchial obstruction symptoms in both adults and children. Since July 2020, the drug has been co-promoted in China by German pharmaceutical giant Bayer under a partnership agreement with Chiesi Farmaceutici SpA. Jemincare’s generic version is expected to enhance accessibility and affordability for patients in China.-Fineline Info & Tech